AU678831B2 - Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof - Google Patents

Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof Download PDF

Info

Publication number
AU678831B2
AU678831B2 AU67540/94A AU6754094A AU678831B2 AU 678831 B2 AU678831 B2 AU 678831B2 AU 67540/94 A AU67540/94 A AU 67540/94A AU 6754094 A AU6754094 A AU 6754094A AU 678831 B2 AU678831 B2 AU 678831B2
Authority
AU
Australia
Prior art keywords
kinase
compound
phosphatidylinositol
wortmannin
acetoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU67540/94A
Other languages
English (en)
Other versions
AU6754094A (en
Inventor
Rosanne Bonjouklian
Garth Powis
Chris John Vlahos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Arizona's Public Universities
Original Assignee
Eli Lilly and Co
University of Arizona
Arizona's Public Universities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co, University of Arizona, Arizona's Public Universities filed Critical Eli Lilly and Co
Publication of AU6754094A publication Critical patent/AU6754094A/en
Application granted granted Critical
Publication of AU678831B2 publication Critical patent/AU678831B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
AU67540/94A 1993-07-19 1994-07-18 Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof Ceased AU678831B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US094279 1993-07-19
US08/094,279 US5378725A (en) 1993-07-19 1993-07-19 Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof

Publications (2)

Publication Number Publication Date
AU6754094A AU6754094A (en) 1995-01-27
AU678831B2 true AU678831B2 (en) 1997-06-12

Family

ID=22244209

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67540/94A Ceased AU678831B2 (en) 1993-07-19 1994-07-18 Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof

Country Status (16)

Country Link
US (1) US5378725A (2)
EP (1) EP0635268A1 (2)
JP (1) JPH0753370A (2)
KR (1) KR950002755A (2)
CN (1) CN1111127A (2)
AU (1) AU678831B2 (2)
CA (1) CA2128046A1 (2)
CZ (1) CZ283806B6 (2)
HU (1) HUT67667A (2)
IL (1) IL110325A0 (2)
NO (1) NO942641L (2)
PH (1) PH30794A (2)
PL (1) PL304317A1 (2)
RU (1) RU94026082A (2)
TW (1) TW287102B (2)
ZA (1) ZA945103B (2)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504103A (en) * 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5468773A (en) * 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US7863429B2 (en) * 1995-12-21 2011-01-04 Qlt Inc. Treatment of inflammatory diseases including psoriasis
US5910417A (en) * 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
US7670767B1 (en) * 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
WO2000018885A1 (en) * 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
AU2855399A (en) * 1998-03-24 1999-10-18 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
US6413773B1 (en) * 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) * 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
AU1330901A (en) * 1999-10-06 2001-05-10 Brigham And Women's Hospital Compounds and methods for modulating non-transcriptional effects of steroid hormones
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6777439B2 (en) * 2000-05-30 2004-08-17 Advanced Research & Technology Institute, Inc. Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
US7235523B2 (en) * 2001-04-13 2007-06-26 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US6703414B2 (en) * 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) * 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
CA2491555C (en) * 2002-07-10 2012-09-11 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
GB0304632D0 (en) * 2003-02-28 2003-04-02 Proxara Biotechnology Ltd Method
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US20050054103A1 (en) * 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
MXPA05011248A (es) * 2003-04-23 2005-12-14 Wyeth Corp Derivados de wortmanina solubles en agua.
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
IL161903A0 (en) * 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
EP1663978B1 (en) * 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
AU2004265149A1 (en) 2003-08-13 2005-02-24 Kudos Pharmaceuticals Limited Aminopyrones and their use as ATM inhibitors
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
WO2006030442A2 (en) * 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
BRPI0515498A (pt) 2004-09-20 2008-07-29 Kudos Pharm Ltd inibidores de dna-pk
EP1799699A1 (en) * 2004-10-13 2007-06-27 Wyeth Analogs of 17-hydroxywortmannin as pi3k inhibitors
CN100369632C (zh) * 2004-10-14 2008-02-20 孔庆忠 抗癌药物组合物
CN1875959B (zh) * 2004-10-14 2010-05-12 孔庆忠 一种抗癌药物组合物
EP1848712A1 (en) 2005-02-09 2007-10-31 Kudos Pharmaceuticals Ltd Atm inhibitors
WO2006089106A2 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
AR053358A1 (es) 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
EP1886138A4 (en) * 2005-05-11 2009-04-15 Genetic Technologies Ltd METHODS FOR ENRICHING FETAL CELLS
CA2609387A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
JP2007063205A (ja) * 2005-08-31 2007-03-15 Japan Science & Technology Agency 神経因性疼痛治療剤
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
JP2010509316A (ja) * 2006-11-09 2010-03-25 ガミダ セル リミテッド 末梢血管疾患を治療するためのエクスビボ培養された造血細胞の使用
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20100109416A1 (en) * 2008-11-03 2010-05-06 Jones Margaret L Adjustable safety harness
KR20160091440A (ko) 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
BRPI1012333A2 (pt) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
AP2011005956A0 (en) * 2009-04-20 2011-10-31 Gilead Calistoga Llc Methods of treatment for solid tumors.
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
BRPI1107182B1 (pt) * 2011-12-29 2022-03-08 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
HK1202581A1 (en) 2012-02-13 2015-10-02 Gamida-Cell Ltd. Mesenchymal stem cells conditioned medium and methods of generating and using the same
NZ629684A (en) 2012-03-05 2016-10-28 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
NZ736970A (en) 2013-12-20 2018-11-30 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
MA40059A (fr) 2014-06-13 2015-12-17 Gilead Sciences Inc Inhibiteurs de la phosphatidylinositol 3-kinase
CN104774239B (zh) * 2015-03-13 2017-01-04 暨南大学 多节孢绿胶霉素类化合物及其用途
CN107058137B (zh) * 2017-06-14 2020-02-07 海正药业(杭州)有限公司 一种渥曼青霉及其生产渥曼青霉素的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668222A (en) * 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988682A (en) * 1989-02-03 1991-01-29 University Of Pittsburgh Myo-inositol analogs and method for their use
JPH0328948A (ja) * 1989-06-27 1991-02-07 Nec Corp 入出力制御装置の動作状態情報収集方式

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668222A (en) * 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin

Also Published As

Publication number Publication date
NO942641D0 (no) 1994-07-14
HU9402128D0 (en) 1994-09-28
ZA945103B (en) 1996-03-27
PH30794A (en) 1997-10-17
PL304317A1 (en) 1995-01-23
CN1111127A (zh) 1995-11-08
TW287102B (2) 1996-10-01
US5378725A (en) 1995-01-03
KR950002755A (ko) 1995-02-16
CZ283806B6 (cs) 1998-06-17
CA2128046A1 (en) 1995-01-20
HUT67667A (en) 1995-04-28
CZ169294A3 (en) 1995-02-15
RU94026082A (ru) 1996-05-20
JPH0753370A (ja) 1995-02-28
AU6754094A (en) 1995-01-27
NO942641L (no) 1995-01-20
IL110325A0 (en) 1994-10-21
EP0635268A1 (en) 1995-01-25

Similar Documents

Publication Publication Date Title
AU678831B2 (en) Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5504103A (en) Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5726167A (en) Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US5468773A (en) Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5441947A (en) Methods of inhibiting vascular restenosis
EP0762879B1 (en) Stereochemical wortmannin derivatives
Hirano et al. Antiproliferative activity of mammalian lignan derivatives against the human breast carcinoma cell line, ZR-75-1
Chang et al. Isolation and partial characterization of a cholesterol-requiring mutant of Chinese hamster ovary cells.
EP1435941B1 (en) Wortmannin analogs and methods of using same
CN104892622B (zh) 嗜氮酮类化合物及其制备方法和用途
GB2302021A (en) Inhibiting bone loss or resorption
US7335679B2 (en) Wortmannin analogs and methods of using same
CA1232853A (en) Cl-1724 antibiotic/antitumor compounds, their production and use
US8586626B2 (en) Metabolites of wortmannin analogs and methods of using the same
EP0722940B1 (en) Physiologically active substances PF1092A, PF1092B and PF1092C, process for the production thereof, and contraceptives and anticancer drugs containing the same as active ingredients
US5338758A (en) Bicyclic diterpene PAF antagonist compounds
MXPA02010297A (es) Ciclopostina, metodo para su produccion y su uso.
JP4109625B2 (ja) ユーロチノンおよびその誘導体、それらを製造する方法、ならびにその使用
EP0337413A2 (en) Naphthopyran derivatives and use thereof
IE914520A1 (en) Phenoxanes, process for the preparation thereof and¹compositions
KR19990075383A (ko) 스트렙토마이세츠 스피시즈 와이 비 401에서 생산되는 마크로락틴 에프를 이용한 콜레스테롤 생합성의억제 방법